Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Mallika Singh, Elena S. Koltun et al.|Nature|2024Cited by 319
Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i> Mutant Pancreatic CancerCraig M. Goodwin, Channing J. Der, Andrew M. Waters et al.|Cancer Research|2022Cited by 160
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant CancersIrem Ozkan‐Dagliyan, Channing J. Der, J. Nathaniel Diehl et al.|Cell Reports|2020Cited by 108
Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell CarcinomaSehrish Javaid, Adrienne D. Cox, Antje Schaefer et al.|Molecular Cancer Therapeutics|2022Cited by 18
Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 CellsAndrew M. Waters, James L. Hartley|PLoS ONE|2016Cited by 13